Spoken Alpha
UNITED THERAPEUTICS Corp
United Therapeutics develops and markets pharmaceutical therapies and medical devices to treat pulmonary arterial hypertension and other rare lung diseases, as well as a cancer immunotherapy.
UNITED THERAPEUTICS Corp is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $21.53B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for UTHR.
$ curl https://api.spokenalpha.com/v1/companies/UTHRFAQ
Spoken Alpha indexes UTHR's earnings call transcripts at https://spokenalpha.com/companies/UTHR. Each call links to attributed speakers and parsed analyst Q&A. UNITED THERAPEUTICS Corp's own investor relations page is at https://ir.unither.com/.
UNITED THERAPEUTICS Corp (UTHR) held its most recent earnings call on 2026-05-06, covering fiscal Q1 2026.
UNITED THERAPEUTICS Corp (UTHR) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $6.38 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-04 | $7.27 | $6.82 | +6.6% | $783.3M | — | — | EODHD |
| Q1 FY2026 | 2026-05-05 | $5.82 | $6.86 | -15.2% | $781.5M | — | — | EODHD |
| Q4 FY2025 | 2026-02-24 | $7.70 | $7.10 | +8.5% | $790.2M | — | — | EODHD |
| Q3 FY2025 | 2025-10-28 | $7.16 | $6.96 | +2.9% | $799.5M | — | — | EODHD |
| Q2 FY2025 | 2025-07-29 | $6.41 | $7.30 | -12.2% | $798.6M | — | — | EODHD |
| Q1 FY2025 | 2025-04-29 | $6.63 | $6.54 | +1.4% | $794.4M | — | — | EODHD |
| Q4 FY2024 | 2025-02-18 | $6.19 | $6.27 | -1.2% | $735.9M | — | — | EODHD |
| Q3 FY2024 | 2024-10-29 | $7.07 | $7.12 | -0.7% | $748.9M | — | — | EODHD |
| Q2 FY2024 | 2024-07-30 | $5.85 | $6.41 | -8.7% | $714.9M | — | — | EODHD |
| Q1 FY2024 | 2024-04-30 | $6.17 | $5.59 | +10.4% | $677.7M | — | — | EODHD |
| Q4 FY2023 | 2024-02-20 | $4.36 | $4.19 | +4.1% | $614.7M | — | — | EODHD |
| Q3 FY2023 | 2023-10-31 | $5.38 | $5.04 | +6.8% | $609.4M | — | — | EODHD |
| Q2 FY2023 | 2023-08-01 | $5.24 | $4.78 | +9.6% | $596.5M | — | — | EODHD |
| Q1 FY2023 | 2023-05-02 | $4.86 | $4.71 | +3.2% | $506.9M | — | — | EODHD |
| Q4 FY2022 | 2023-02-21 | $2.67 | $4.51 | -40.8% | $491.5M | — | — | EODHD |
| Q3 FY2022 | 2022-11-01 | $4.91 | $3.77 | +30.2% | $516.0M | — | — | EODHD |
| Q2 FY2022 | 2022-08-02 | $3.46 | $4.54 | -23.8% | $466.9M | — | — | EODHD |
| Q1 FY2022 | 2022-05-03 | $5.03 | $3.07 | +63.8% | $461.9M | — | — | EODHD |
| Q4 FY2021 | 2022-02-23 | $2.35 | $3.72 | -36.8% | $415.2M | — | — | EODHD |
Source: EODHD. UTHR reported actuals as published; sparse fields render as —.